Personalized Stem Cells Announces Brazilian Clearance of Long-Haul COVID Study Licensed to Sorrento Therapeutics
EINPresswire,
Personalized Stem Cells announces Brazilian authorization for Phase 2 long-haul COVID stem cell clinical trial.
Personalized Stem Cells announces Brazilian authorization for Phase 2 long-haul COVID stem cell clinical trial.
Personalized Stem Cells announces first patient enrolled in Phase 2 Brazilian COVID-19 stem cell clinical trial licensed to…
SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr.
GlobeNewswire 2021-09-13 SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr.
In this article: SAN DIEGO, Sept. 13, 2021 Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr.
SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr.
SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. SAN DIEGO, Sept.
SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr.
Tags: Press Release COVI-MSC Sorrento ARDS COVID-19 Pulmonary/Respiratory Medicine Clinical Research (R
First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil.
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announcedtodaythe start of…
First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil.
GlobeNewswire 2021-09-02 First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil.
First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil.
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today the start…
First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil.
First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil.
First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil.
First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil.
First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil.
In this article: First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil.
First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil.
First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil.
Personalized Stem Cells announces Brazilian authorization for Phase 2 COVID-19 stem cell clinical trial licensed to Sorrento…
Personalized Stem Cells announces enrollment is complete for COVID-19 FDA approved stem cell clinical trial licensed to…
Personalized Stem Cells announces enrollment is complete for COVID-19 FDA approved stem cell clinical trial licensed to…
Personalized Stem Cells, Inc. announces additional positive results in COVID-19 FDA approved stem cell clinical trial licensed…
All nine patients with acute respiratory failure due to COVID-19 discharged from hospital within days after 3rd COVI-MSC…
All nine patients with acute respiratory failure due to COVID-19 discharged from hospital within days after 3 rd COVI-MSC…
By: GlobenewsWire - 25 Mar 2021 All nine patients with acute respiratory failure due to COVID-19 discharged from hospital…
All nine patients with acute respiratory failure due to COVID-19 discharged from hospital within days after 3rd COVI-MSC…
All nine patients with acute respiratory failure due to COVID-19 discharged from hospital within days after 3 rd COVI-MSC…
Thisongoingstudy (MSC-COV-101) is a single arm, non-randomized Phase 1b study of the safety and preliminary efficacy ofCOVI-MSCsa…
All nine patients with acute respiratory failure due to COVID-19 discharged from hospital within days after 3rd COVI-MSC…
All nine patients with acute respiratory failure due to COVID-19 discharged from hospital within days after 3 rd COVI-MSC…
All nine patients with acute respiratory failure due to COVID-19 discharged from hospital within days after 3 rd COVI-MSC…
All nine patients with acute respiratory failure due to COVID-19 discharged from hospital within days after 3 rd COVI-MSC…
All nine patients with acute respiratory failure due to COVID-19 discharged from hospital within days after 3 rd COVI-MSC…
All nine patients with acute respiratory failure due to COVID-19 discharged from hospital within days after 3 rd COVI-MSC…
All nine patients with acute respiratory failure due to COVID-19 discharged from hospital within days after 3 rd COVI-MSC…
All nine paiens wih acue respiraory failure due o COVID-19 discharged from hospial wihin days afer 3rd COVI-MSC…
All nine patients with acute respiratory failure due to COVID-19 discharged from hospital within days after 3 rd COVI-MSC…
Personalized Stem Cells, Inc. announces first patients treated in COVID-19 FDA approved stem cell clinical trial licensed to…
SAN DIEGO - (Nasdaq: SRNE, 'Sorrento') announced today additional positive results from its Phase 1b study of human allogeneic…
Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC…
@media screen and (min-width:1201px){.ujtzu6017da8da5616{display:block}}@media screen and (min-width:993px) and (max-width:1200px…
Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC…
Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC…
Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC…
The primaryobjectiveis to evaluate the safety of intravenous infusion of allogeneic adiposeMSCcells in patients with COVID-19-ind…
By: GlobenewsWire - 31 Jan 2021 Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical…
Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC…
Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC…
Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC…
| Source:Sorrento Therapeutics, Inc. Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical…
GlobeNewswire Update to 01/26/21 COVI-MSC™ Press Release: Fourth Patient Also Released From Hospital Following Third Infusion…
Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC…
· Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC…
· Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC…
Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC…
Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC…
Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC…
Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC…
Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC…
Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC…
Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC…
Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC…
Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC…
Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC…
First three patients discharged from Hospital ICU within 8 days from initial IV administration No infusion-related adverse…
SAN DIEGO - (Nasdaq: SRNE, 'Sorrento') announced today positive preliminary results from its Phase 1b study of human allogeneic…
First three patients discharged from Hospital ICU within 8 days from initial IV administration No infusion-related adverse…
@media screen and (min-width:1201px){.rjlgl601146fa86079{display:block}}@media screen and (min-width:993px) and (max-width:1200px…
First three patients discharged from Hospital ICU within 8 days from initial IV administration No infusion-related adverse…
First three patients discharged from Hospital ICU within 8 days from initial IV administration No infusion-related adverse…
First three patients discharged from Hospital ICU within 8 days from initial IV administration No infusion-related adverse…
Thisongoingstudy (PSC-CP-004) is a single arm, non-randomized Phase 1b study of the safety and preliminary efficacy ofCOVI-MSCsad…
By: GlobenewsWire - 27 Jan 2021 First three patients discharged from Hospital ICU within 8 days from initial IV administration…
First three patients discharged from Hospital ICU within 8 days from initial IV administration No infusion-related adverse…
First three patients discharged from Hospital ICU within 8 days from initial IV administration  No infusion-related…
First three patients discharged from Hospital ICU within 8 days from initial IV administration No infusion-related adverse…
· First three patients discharged from Hospital ICU within 8 days from initial IV administration · No infusion-related adverse…
· First three patients discharged from Hospital ICU within 8 days from initial IV administration · No infusion-related adverse…
First three patients discharged from Hospital ICU within 8 days from initial IV administration No infusion-related adverse…
First three patients discharged from Hospital ICU within 8 days from initial IV administration No infusion-related adverse…
First three patients discharged from Hospital ICU within 8 days from initial IV administration No infusion-related adverse…
First three patients discharged from Hospital ICU within 8 days from initial IV administration No infusion-related adverse…
First three patients discharged from Hospital ICU within 8 days from initial IV administration No infusion-related adverse…
First three patients discharged from Hospital ICU within 8 days from initial IV administration No infusion-related adverse…
First three patients discharged from Hospital ICU within 8 days from initial IV administration No infusion-related adverse…
First three patients discharged from Hospital ICU within 8 days from initial IV administration No infusion-related adverse…
SAN DIEGO, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc.,. (Nasdaq: SRNE, "Sorrento") announced today positive…
SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced that it will be…
Personalized Stem Cells enters exclusive licensing agreement with Sorrento Therapeutics for allogeneic stem cell platform…
SAN DIEGO - (Nasdaq: SRNE, 'Sorrento') announced today that it has entered into an exclusive license agreement with (PSC) to…
] SAN DIEGO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it…
The study is a single arm, non-randomized Phase 1 study of the safety and preliminary efficacy of an adipose-derived allogeneic…
SAN DIEGO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has…
SAN DIEGO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has…